Resources>Citations Database>Engineered extracellular vesicles with DR5 agonistic scFvs simultaneously target tumor and immunosuppressive stromal cells

Engineered extracellular vesicles with DR5 agonistic scFvs simultaneously target tumor and immunosuppressive stromal cells

Biointron 2025-01-15

Authors: Yeye Guo, Huaishan Wang, Shujing Liu, Xiaogang Zhang, Xingyue Zhu, Lili Huang, Wenqun Zhong, Lei Guan, Yeqing Chen, Min Xiao, Lingling Ou, Jingbo Yang, Xiang Chen, Alexander C. Huang, Tara Mitchell, Ravi Amaravadi, Giorgos Karakousis, John Miura, Lynn Schuchter, Ahron Flowers, Qiuxian Zheng, Haiwei Mou, Phyllis Gimotty, Meenhard Herlyn, Wei Guo, and Xiaowei Xu

Journal: Science Advances

PubMed ID: 39813334

DOI: https://doi.org/10.1126/sciadv.adp9009

Products & Services: DR5 monoclonal antibodies (tigatuzumab) were manufactured by Biointron

Subscribe to our Citations Database
Recommended Articles
MRNA Profiling Involved in Triggering of STAT1 with Regulatory Involvement of IRF7, PTPRF, and miR-145p in Patients Suffering from Gall Bladder Carcinoma
Nov 25, 2025
Droplet Squeeze Microfluidic Platform for Generating Extracellular Vesicle Hybrids for Drug Delivery

Droplet Squeeze Microfluidic Platform for Generating Extracellular Vesicle Hybri……

Aug 07, 2025
Self-Assembling Multi-Antigen T Cell Hybridizers for Precision Immunotherapy of Multiple Myeloma

Self-Assembling Multi-Antigen T Cell Hybridizers for Precision Immunotherapy of ……

Aug 01, 2025
Inhibition of long-lived plasma cells, a critical role for Telitacicept treatment to systemic lupus erythematosus

Inhibition of long-lived plasma cells, a critical role for Telitacicept treatmen……

Jul 30, 2025

Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.